MARKET

SLXN

SLXN

Silexion Therapeutics Corp
NASDAQ
1.700
+0.050
+3.03%
Opening 12:49 03/06 EST
OPEN
1.650
PREV CLOSE
1.650
HIGH
1.700
LOW
1.650
VOLUME
6.26K
TURNOVER
--
52 WEEK HIGH
26.70
52 WEEK LOW
1.420
MARKET CAP
5.66M
P/E (TTM)
-0.0674
1D
5D
1M
3M
1Y
5Y
1D
Silexion Therapeutics urges shareholders to vote ahead of EGM
TipRanks · 1d ago
Weekly Report: what happened at SLXN last week (0223-0227)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 02/24 21:05
Weekly Report: what happened at SLXN last week (0216-0220)?
Weekly Report · 02/23 10:17
Silexion Therapeutics is developing a potential “holy grail” play in precision oncology (NASDAQ: SLXN)
TipRanks · 02/17 13:00
Weekly Report: what happened at SLXN last week (0209-0213)?
Weekly Report · 02/16 10:17
Silexion Therapeutics Corp. Announces Date for Extraordinary General Meeting
Reuters · 02/13 21:10
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 02/10 12:05
More
About SLXN
Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXN stock methods without spending real money on the virtual paper trading platform.